No go for Zosano as FDA knockback triggers suspension of transdermal migraine patch program

No go for Zosano as FDA knockback triggers suspension of transdermal migraine patch program

Source: 
Fierce Pharma
snippet: 

Zosano Pharma’s headaches are intensifying. With the FDA again knocking back its transdermal migraine patch, the biotech has suspended its M207 program and made more layoffs to preserve its dwindling cash reserves.